Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of June 2021. The report serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of a specific securities transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single transaction involving the acquisition of American Depositary Shares (ADSs) by Dr. H. Barron, Chief Scientific Officer and President, R&D.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of an insider transaction executed on June 22, 2021, on the New York Stock Exchange.
Important Facts for Investors
- Transaction Type: Acquisition of notional ADSs within an Executive Supplemental Savings Plan account.
- Executive Involved: Dr. H. Barron (Chief Scientific Officer and President, R&D).
- Transaction Date: June 22, 2021.
- Volume: 1,184.8419 ADSs.
- Price: $39.08 per ADS.
- Exchange: New York Stock Exchange (XNYS).